The launch of premium mods on console expands monetization opportunities for modders and indicates an exponential growth opportunity for the ARK Universe
May 30, 2024
Annual Event Showcases the Power of Creativity and the Innovation of Next Generation Technology in Hong Kong
May 30, 2024
Expected to expand global business in the Chinese market SEOUL,South Korea,May 24,2024-- SEMIFIVE,a leading design solution provider and pioneer of platform-based custom silicon solutions,has announc
May 30, 2024
LONDON,May 23,2024-- Over the course of the flat panel display (FPD) industry\'s history,factory utilization has typically averaged approximately 84%. However,from 3Q22 to 4Q23,as theFPD market strug
May 30, 2024
BEIJING,May 23,2024-- Recon Technology,Ltd. (NASDAQ: RCON) ("Recon" or the "Company") announced today that on May 22,2024,it had received a letter dated May 22,2024 (the "Comp
May 30, 2024
CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas,and among the top two globally in clinical development.
May 30, 2024
EBENE CYBERCITY,Mauritius,May 24,2024-- Ultima Markets,one of the fastest-growing online trading brokers,is proud to announce its partnership with Willis Towers Watson (WTW) to enhance its client\'s
May 30, 2024
HYDERABAD,India,May 24,2024--Hyderabad, the City of Pearls in India,witnessed the unveiling of its newest crowning jewel – Megaleio,an opulent residential project designed to redefine luxury living.
May 30, 2024
Oral Presentation:a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in patients with cervical cancer
May 30, 2024
The unique event,which is among the first global events created to build excitement for the upcoming Olympic Games,sees French andSingaporeans athletes and artists coming together to revitalise the ic
May 30, 2024
The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options.
May 30, 2024
Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression,including in patients with PD-L1 CPS<5.
May 30, 2024
© TopicFashion Privacy Policy Contact us